MX2022013927A - Composiciones y metodos para tratar la epilepsia. - Google Patents

Composiciones y metodos para tratar la epilepsia.

Info

Publication number
MX2022013927A
MX2022013927A MX2022013927A MX2022013927A MX2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A
Authority
MX
Mexico
Prior art keywords
methods
treating epilepsy
compositions
administering
inhibitor
Prior art date
Application number
MX2022013927A
Other languages
English (en)
Spanish (es)
Inventor
Ted Yednock
Sethu Sankaranarayanan
Jeanne T Paz
Original Assignee
The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Glads
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Glads filed Critical The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Glads
Publication of MX2022013927A publication Critical patent/MX2022013927A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022013927A 2020-05-05 2021-05-05 Composiciones y metodos para tratar la epilepsia. MX2022013927A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063020245P 2020-05-05 2020-05-05
PCT/US2021/030930 WO2021242493A2 (en) 2020-05-05 2021-05-05 Compositions and methods for treating epilepsy

Publications (1)

Publication Number Publication Date
MX2022013927A true MX2022013927A (es) 2022-11-30

Family

ID=78745740

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013927A MX2022013927A (es) 2020-05-05 2021-05-05 Composiciones y metodos para tratar la epilepsia.

Country Status (8)

Country Link
US (1) US20240034775A1 (enExample)
EP (1) EP4146276A4 (enExample)
JP (1) JP2023524819A (enExample)
CN (1) CN115996752B (enExample)
AU (1) AU2021278819A1 (enExample)
CA (1) CA3177879A1 (enExample)
MX (1) MX2022013927A (enExample)
WO (1) WO2021242493A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912396T3 (es) * 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
SG11201510316UA (en) * 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
PL3215527T3 (pl) * 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
JP6779876B2 (ja) * 2014-11-19 2020-11-04 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
IL309260B2 (en) * 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
US20190161535A1 (en) * 2016-05-09 2019-05-30 Annexon, Inc. Compositions and methods for treating spinal muscular atrophy
EP3487531A4 (en) * 2016-07-19 2020-03-25 Annexon, Inc. TREATMENT OF FRONTO-TEMPORAL DEMENTIA
CN112867394B9 (zh) * 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
MX2021004819A (es) * 2018-11-02 2021-06-08 Annexon Inc Composiciones y metodos para tratar lesiones cerebrales.
WO2020124013A1 (en) * 2018-12-13 2020-06-18 Gryphon Bio, Inc. Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair

Also Published As

Publication number Publication date
CN115996752A (zh) 2023-04-21
WO2021242493A2 (en) 2021-12-02
JP2023524819A (ja) 2023-06-13
CN115996752B (zh) 2025-04-01
AU2021278819A1 (en) 2022-11-24
EP4146276A4 (en) 2024-08-14
CA3177879A1 (en) 2021-12-02
EP4146276A2 (en) 2023-03-15
WO2021242493A3 (en) 2022-06-09
US20240034775A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
MY208545A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
WO2020104648A3 (en) TGFβ INHIBITOR AND PRODRUGS
MY206796A (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
PH12020551995A1 (en) Modulator of apol1 expression
PH12021551463A1 (en) Modulators of hsd17b13 expression
MY194227A (en) Modulators of pcsk9 expression
NI202100018A (es) Moduladores de la expresión de pnpla3
PH12022550130A1 (en) Enzyme inhibitors
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2024010804A (es) Butirato alimenticio para tratar o prevenir un trastorno alergico.
WO2021242493A3 (en) Compositions and methods for treating epilepsy
PH12022550118A1 (en) Enzyme inhibitors
BR112022003768A2 (pt) Compostos inibidores de perk
MX2024008831A (es) Terapia combinada para carcinoma hepatocelular.
MX2021008918A (es) Moduladores de expresion yap1.
ZA202103914B (en) Cxcr7 inhibitors for the treatment of cancer
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
WO2020086954A3 (en) Treatments for charcot-marie-tooth disease
PH12021552499A1 (en) Methods for the treatment of beta-thalassemia
MX2021009535A (es) Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.
WO2019173478A3 (en) Combination of depletes tregs and a checkpoint inhibitor
BR112022001602A2 (pt) Composição e método para prevenir, aliviar ou tratar lesão hepática
MX2024012789A (es) Inhibidores de fosfoinositida 3-cinasa alfa (pi3kalfa)